Forum

Events

Partner Content

Last year we told you that the cell and gene industry would be worth $9 - $14 billion by 2026. We were wrong.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.